287 related articles for article (PubMed ID: 31366386)
1. Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival.
Sorrentino C; Yin Z; Ciummo S; Lanuti P; Lu LF; Marchisio M; Bellone M; Di Carlo E
J Immunother Cancer; 2019 Jul; 7(1):201. PubMed ID: 31366386
[TBL] [Abstract][Full Text] [Related]
2. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
3. Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression.
Belle L; Agle K; Zhou V; Yin-Yuan C; Komorowski R; Eastwood D; Logan B; Sun J; Ghilardi N; Cua D; Williams CB; Gaignage M; Marillier R; van Snick J; Drobyski WR
Blood; 2016 Oct; 128(16):2068-2082. PubMed ID: 27488350
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating regulatory T cells, CD8/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer.
Solis-Castillo LA; Garcia-Romo GS; Diaz-Rodriguez A; Reyes-Hernandez D; Tellez-Rivera E; Rosales-Garcia VH; Mendez-Cruz AR; Jimenez-Flores JR; Villafana-Vazquez VH; Pedroza-Gonzalez A
Breast Cancer; 2020 Sep; 27(5):837-849. PubMed ID: 32180141
[TBL] [Abstract][Full Text] [Related]
5. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
[TBL] [Abstract][Full Text] [Related]
6. INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts.
Yu Y; Huang R; Zong X; He X; Mo W
BMC Cancer; 2016 Jul; 16():397. PubMed ID: 27389040
[TBL] [Abstract][Full Text] [Related]
7. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4
Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET
J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845
[TBL] [Abstract][Full Text] [Related]
8. Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue.
Valdman A; Jaraj SJ; Compérat E; Charlotte F; Roupret M; Pisa P; Egevad L
APMIS; 2010 May; 118(5):360-5. PubMed ID: 20477811
[TBL] [Abstract][Full Text] [Related]
9. A requirement of dendritic cell-derived interleukin-27 for the tumor infiltration of regulatory T cells.
Xia S; Wei J; Wang J; Sun H; Zheng W; Li Y; Sun Y; Zhao H; Zhang S; Wen T; Zhou X; Gao JX; Wang P; Wu Z; Zhao L; Yin Z
J Leukoc Biol; 2014 May; 95(5):733-742. PubMed ID: 24443555
[TBL] [Abstract][Full Text] [Related]
10. Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma.
Schneider T; Kimpfler S; Warth A; Schnabel PA; Dienemann H; Schadendorf D; Hoffmann H; Umansky V
J Thorac Oncol; 2011 Mar; 6(3):432-8. PubMed ID: 21258248
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes.
Sharma MD; Hou DY; Liu Y; Koni PA; Metz R; Chandler P; Mellor AL; He Y; Munn DH
Blood; 2009 Jun; 113(24):6102-11. PubMed ID: 19366986
[TBL] [Abstract][Full Text] [Related]
13. [Proliferation of CD4+ CD25+ regulatory T cells of rat by different cytokines in vitro].
Wang ZH; Zhu JY; Li T; Leng XS
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(12):844-7. PubMed ID: 18756991
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin virus-like particle immunization controls pancreatic cancer growth through CD8+ T cell induction and reduction in the frequency of CD4+ foxp3+ ICOS- regulatory T cells.
Zhang S; Yong LK; Li D; Cubas R; Chen C; Yao Q
PLoS One; 2013; 8(7):e68303. PubMed ID: 23874581
[TBL] [Abstract][Full Text] [Related]
15. CD4
Kindlund B; Sjöling Å; Yakkala C; Adamsson J; Janzon A; Hansson LE; Hermansson M; Janson P; Winqvist O; Lundin SB
Gastric Cancer; 2017 Jan; 20(1):116-125. PubMed ID: 26782287
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F; Zhao Y; Wei L; Li S; Liu J
Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
[TBL] [Abstract][Full Text] [Related]
17. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.
Sharma MD; Baban B; Chandler P; Hou DY; Singh N; Yagita H; Azuma M; Blazar BR; Mellor AL; Munn DH
J Clin Invest; 2007 Sep; 117(9):2570-82. PubMed ID: 17710230
[TBL] [Abstract][Full Text] [Related]
18. Exogenous interleukin-33 targets myeloid-derived suppressor cells and generates periphery-induced Foxp3⁺ regulatory T cells in skin-transplanted mice.
Gajardo T; Morales RA; Campos-Mora M; Campos-Acuña J; Pino-Lagos K
Immunology; 2015 Sep; 146(1):81-8. PubMed ID: 25988395
[TBL] [Abstract][Full Text] [Related]
19. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection.
Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM
J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253
[TBL] [Abstract][Full Text] [Related]
20. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.
Pallandre JR; Brillard E; Créhange G; Radlovic A; Remy-Martin JP; Saas P; Rohrlich PS; Pivot X; Ling X; Tiberghien P; Borg C
J Immunol; 2007 Dec; 179(11):7593-604. PubMed ID: 18025205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
